[BCG therapy in NMIBC: How much and for how long?.]
Bladder cancer is the 9th most prevalent cancer in the world. It is divided into muscle invasive bladder cancer (MIBC) and non muscle invasive bladder cancer (NMIBC). Over 75% belong to the second group and it will be classified according to the risk of progression and recurrence. In high and intermediate risk tumors. There is indication for the use of bladder instillations with BCG as it reduces the number of recurrences and disease progression to MIBC. In spite of this, disease control is not possible in all cases and there could be recurrence or progression of the disease to MIBC. This article is a review of the therapeutic options of tumor recurrence after failure of BCG treatment.